Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China

Qingqing Chen, Zhencang Zheng, Chao Zhang, Xijiang Zhang, Huijuan Wu, Jingdong Wang, Shuwei Wang, Cheng ZhengInfection 2020 · DOI

Abstract

Older patients or patients with comorbidities such as obesity or diabetes mellitus were more likely to have severe condition. Treatments of COVID-19 is still experimental and more clinical trials are needed.

Introduction

In the early stages of the 2020 pandemic, clinical data primarily emerged from Wuhan. However, as the virus spread, regional hubs like Taizhou in Zhejiang province—a city with significant economic and travel ties to Wuhan—became critical sites for understanding the "imported" phase of the outbreak. This study provides a retrospective analysis of 145 laboratory-confirmed COVID-19 patients in Taizhou, aiming to identify clinical markers that distinguish severe from non-severe cases.

Methods

Researchers conducted a single-center retrospective observational study at the Taizhou Public Health Medical Center. The cohort included 145 patients admitted between January 1 and March 11, 2020, all confirmed via RT-PCR. Severity was defined according to the Chinese National Health Commission's guidelines, focusing on respiratory rate, oxygen saturation, and oxygenation index. Statistical analyses compared demographic data, comorbidities, laboratory results, and imaging findings between severe and non-severe groups.

Clinical Characteristics and Risk Factors

The study identified several key predictors of disease severity:

  • Age and BMI: The average age of the cohort was 47.5 years, but patients in the severe group were significantly older (mean 52.8 years) than those in the non-severe group (45.3 years). Notably, a higher Body Mass Index (BMI) was strongly associated with severity (mean 24.78 in severe cases vs. 23.20 in non-severe cases), providing early evidence of obesity as a risk factor.
  • Symptom Presentation: While dry cough (81.4%) and fever (75.2%) were the most prevalent symptoms, nearly 25% of patients were afebrile at onset. Severe cases were more likely to present with anorexia (60.5%) and chest tightness (60.5%).

Laboratory and Radiographic Findings

Laboratory data revealed a distinct inflammatory "signature" in severe patients, characterized by higher neutrophil counts, lower lymphocyte counts (lymphopenia), and elevated levels of lactate dehydrogenase (LDH) and erythrocyte sedimentation rate (ESR).

Radiographic evidence was equally telling. Bilateral pneumonia was observed in 93% of severe patients compared to 73.5% of non-severe patients. Initial CT scans often showed ground-glass opacities and consolidations, which served as early indicators of potential respiratory decline.

Chest CT scans showing characteristic bilateral ground-glass opacities and lung involvement in COVID-19 patients.

Treatment and Outcomes

The treatment regimen was multifaceted:

  • Antivirals: 97.2% of patients received antiviral therapy, primarily lopinavir/ritonavir or arbidol.
  • Corticosteroids: Glucocorticoid use was significantly higher in the severe group (88% vs. 4.9%).
  • Traditional Medicine: 90.3% of patients were treated with traditional Chinese medicine.

Remarkably, the study reported a 100% discharge rate by March 11, 2020. Only one patient required ICU admission and invasive mechanical ventilation, likely due to the transfer of the most critical cases to provincial-level specialized facilities.

Conclusion and Limitations

While this study offers valuable early-pandemic insights, it is limited by its retrospective nature and relatively small sample size. The 100% survival rate may reflect a selection bias, as the most critical patients were often moved to larger provincial hospitals. Furthermore, the treatments employed were experimental, highlighting the urgent need for randomized clinical trials to establish definitive protocols for COVID-19 management.

Summary updated

Abstract

Older patients or patients with comorbidities such as obesity or diabetes mellitus were more likely to have severe condition. Treatments of COVID-19 is still experimental and more clinical trials are needed.
BibTeX
@inproceedings{chen2020clinical,
  author = {Qingqing Chen and Zhencang Zheng and Chao Zhang and Xijiang Zhang and Huijuan Wu and Jingdong Wang and Shuwei Wang and Cheng Zheng},
  title = {{Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China}},
  booktitle = {Infection},
  year = {2020},
  doi = {10.1007/s15010-020-01432-5},
}
Figure